|68.52 1.13 (1.68%)||12-08 16:00|
|Targets||6-month :||83.16||1-year :||86.64|
|Resists||First :||71.2||Second :||74.18|
|Supports||First :||66.38||Second :||55.23|
|MAs||MA(5) :||68.25||MA(20) :||70.41|
|MA(100) :||69.63||MA(250) :||0|
|MACD||MACD :||-0.3||Signal :||0.2|
|%K %D||K(14,3) :||20.4||D(3) :||21.6|
|52-week||High :||87.83||Low :||53|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GEHC ] has closed above bottom band by 32.6%. Bollinger Bands are 29.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||68.68 - 69.16||69.16 - 69.54|
|Low:||66.14 - 66.66||66.66 - 67.06|
|Close:||67.85 - 68.64||68.64 - 69.26|
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Health Information Services
|Shares Out||455 (M)|
|Shares Float||393 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||77.4 (%)|
|Shares Short||16,550 (K)|
|Shares Short P.Month||14,520 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||15.65|
|Profit Margin||8.9 %|
|Operating Margin||15.2 %|
|Return on Assets (ttm)||6.1 %|
|Return on Equity (ttm)||14.5 %|
|Qtrly Rev. Growth||5.4 %|
|Gross Profit (p.s.)||15.77|
|Sales Per Share||42.35|
|Qtrly Earnings Growth||-23.3 %|
|Operating Cash Flow||2,090 (M)|
|Levered Free Cash Flow||2,440 (M)|
|Price to Book value||4.37|
|Price to Sales||1.61|
|Price to Cash Flow||14.92|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|